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Summary
Objectives: (1) To investigate the effects of exercise and osteochondral (OC) injury on synovial ﬂuid (SF) chondroitin sulfate (CS) and hyalur-
onan (HA) concentration and chain length, (2) to compare SF and cartilage CS data from joints with OC fragmentation, and (3) to compare SF
CS and HA proﬁles with those seen in serum from the same horses.
Methods: Serum and SF were obtained from (1) normal horses after 8 weeks rest, (2) the same horses after 9 months treadmill training, and
(3) horses with OC injury from racing. Articular cartilage was also collected from group 3 horses. Concentrations and chain lengths of CS and
HA were determined by gel chromatography and ﬂuorophore-assisted carbohydrate electrophoresis.
Results: SF CS peak chain length in the OC injury group increased signiﬁcantly (18.7 kDa) when compared to rested horses (11.6 kDa), with
exercise producing an intermediate chain length (15.6 kDa). Cartilage and serum from the OC injury group had the abnormally long CS chains
seen in SF from these horses. Total SF HA was signiﬁcantly lower in the OC injury group compared to the rested group. Both the OC injury
group and the exercised group had signiﬁcant decreases in SF HA chain length compared to the rested group.
Conclusions: Chain length of SF CS was increased by exercise and OC injury. Exercise resulted in a modest increase, whereas OC injury
caused a marked increase. In contrast to CS, SF HA chain length was decreased by OC injury, and to a lesser extent by exercise. Chain
length analysis of SF CS and HA may provide a useful tool for evaluation of joint health.
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SocietyIntroduction
Synovial ﬂuid (SF) glycosaminoglycan (GAG) composition
can vary with age, exercise, and joint injury. The concentra-
tion, isomer composition and immunoreactivity of GAGs,
such as chondroitin sulfate (CS), keratan sulfate, and hya-
luronan (HA) have been widely studied as biomarkers to
monitor changes in the metabolism of joints1e6. Exercise
and injury produce changes in CS sulfation patterns and
concentrations in articular cartilage and SF1,7e13. Although
exercise was reported to have no effect on SF HA concen-
tration14, there are many reports that injury and osteoarthri-
tis (OA) affect SF HA concentration15e20 and chain
length21,22.
Accurate assessment of the role of biomarkers in diagno-
sis has been hampered by the fact that cartilage and SF
samples are seldom available from patients with early OA.
Validation requirements for biomarkers of OA are many,
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and knowledge of its function. There should also be an un-
derstanding of the relationships between changes in carti-
lage metabolism and changes in the biomarker in body
ﬂuid compartments23. As a translational model of OA, the
horse presents a number of advantages. Horses are rela-
tively long-lived (over 30 years) and therefore reduce the
more rapid aging effect seen in other animal models24.
Human and horse cartilage thickness are very similar
(w2 mm), with comparable age-related changes25e27. In
addition, horses are readily adaptable to treadmill exercise,
and equine joints can be repetitively sampled without gen-
eral anesthesia or lavage. SF can be collected concurrently
with blood, which provides abundant sample volumes of
pertinent tissues for multiple biomarker assessment.
Abnormally long CS chains have been reported for
newly synthesized aggrecan in post-injury canine OA car-
tilage28. To date, there is no published study on the effect
of exercise and joint injury on GAG chain length in SF. In
the current study, we have used horses to evaluate the ef-
fects of exercise and injury on the chain lengths of CS and
HA by using paired samples of SF, cartilage, and serum.
Our objective was to compare the structure of these
GAGs in different body compartments to establish poten-
tial metabolic relationships that may lead to simpliﬁed18
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poses of this study were (1) to investigate the effects of
exercise and osteochondral (OC) injury on SF CS and
HA concentration and chain length, (2) to compare SF
and cartilage CS data from joints with OC fragmentation,
and (3) to compare SF CS and HA proﬁles with those
seen in serum.
Materials and methods
STUDY ANIMALS AND EXPERIMENTAL DESIGN
SF and serum were obtained from three groups of
horses: (1) Rested group: SF from the middle carpal joints
of nine Thoroughbred horses (3e6 years of age) after
they had been given pasture rest for 8 weeks. (2) Exercised
group: after 9 months of treadmill exercise, the same joints
from group 1 horses were sampled after a period of maxi-
mal exercise (stress testing) in which treadmill speed was
incrementally increased until the horse could no longer
maintain position on the treadmill. Serum samples were ob-
tained immediately after maximal exercise and then again
1 h later. Over the 9-month period, treadmill exercise was
performed every MondayeWednesdayeFriday, at 4 m/s
(trot) for 0.6 km, then 8 m/s (slow gallop) for 3 km, and
then 4 m/s for 0.4 km, for total distance of 4 km. On
Wednesdays and Fridays, the slow gallop was performed
at a 6 incline. (3) OC injury group: in addition to serum col-
lection, SF and cartilage were collected from 11 middle car-
pal joints of nine Thoroughbred racehorses (3e6 years of
age) undergoing arthroscopic surgery for removal of OC
fragments, which were injuries resulting from racing. These
fragments were removed from the dorsal articular borders of
the third and radiocarpal bones. The protocol was approved
by the University of Florida Institutional Animal Care and
Use Committee. Blood was collected from the jugular vein
via needle venipuncture. After being allowed to clot, serum
samples were centrifuged and decanted. SF was collected
by needle arthrocentesis. If SF samples were contaminated
with blood, they were also centrifuged and decanted. All
samples were stored at 80C until assayed.
PROCEDURES
SF (0.25 ml in 0.75 ml of 0.1 M ammonium acetate, pH 7),
serum (1 ml), and cartilage samples (5e10 mg in 1 ml of
0.1 M ammonium acetate, pH 7) were digested for 6 h
with proteinase K (1 mg proteinase K/sample; GIBCO,
Carlsbad, CA), followed by enzyme inactivation at 100C
for 10 min and ﬁltration through a 0.45 mm nylon mem-
brane. SF digests were then fractionated on gel ﬁltration
columns (HR 10/30; GE Healthcare, Pittsburg, PA) packed
with allyl dextran/bisacrylamide (Sephacryl S-1000, on
which 10% of the sample was loaded; GE Healthcare) or
agarose (Superose 6, on which 90% of the sample was
loaded; GE Healthcare), using 0.1 M ammonium bicarbon-
ate (pH 7) as the mobile phase (0.5 ml/min; FPLC Pump
P-500; GE Healthcare). Serum and cartilage digests
were fractionated only on Superose 6. Columns were
cleaned with 0.1 M sodium hydroxide between samples.
Sephacryl S-1000 has a fractionation range (Mr) of
5 105 to >108. Superose 6 has a range up to 106. Col-
umn efﬂuent was collected in 1 ml fractions by using a frac-
tion collector (GE Healthcare). Fractions 1e6 were
discarded and fractions 7e24 were collected and analyzed
(S-1000 fractions designated A7eA24 and Superose 6fractions designated B7eB24). The Superose 6 column
was previously calibrated for CS molecular weight29.
After drying in a vacuum concentrator (Thermo Electron
Corp., Waltham, MA), fractions were resuspended in 100 ml
of 100 mM ammonium acetate (pH 6.2) and digested with
30 mU each of chondroitinase ABC and chondroitinase
ACII (Seikagaku, Associates of Cape Cod, East Falmouth,
MA) at 37C overnight. Disaccharide digests were vacuum
dried before labeling for ﬂuorophore-assisted carbohydrate
electrophoresis (FACE)30. Labeling was performed by addi-
tion of 5 ml of 0.1 M 2-aminoacridone HCl (25 mg in 150 ml
acetic acid/850 ml dimethyl sulfoxide (DMSO); Molecular
Probes, Carlsbad, CA), followed by incubation at room tem-
perature for 10 min. Then 5 ml of 1 M sodium cyanoborohy-
dride (in ultrapure water; Sigma, St. Louis, MO) was added
and incubated overnight at 37C. Galactose-6-sulfate (60,
120, 240, 480, and 960 pmol; Sigma) was labeled simulta-
neously as an internal standard. On the next day, 30 ml of
25% glycerol was added to each sample, followed by vortex
mixing and then centrifugation at 13,000 g for 2 min.
Components sufﬁcient for pouring two resolving gels con-
sisted of 11.25 ml of 40% acrylamide (Sigma), 1.5 ml of 25%
glycerol, 1.5 ml of 0.45 MTris (hydroxymethyl) aminomethane
buffer (Tris base; Fisher, Pittsburg, PA; pH 7.0), and 0.75 ml of
ultrapure water. After addition of 75 ml of 20% ammonium per-
sulfate (Sigma) in ultrapurewater and15 ml of tetramethylethy-
lenediamine (TEMED; Fisher), the components were mixed
and poured into a 10 cm 10 cm vertical gel system (Owl,
Portsmouth, NH). After the resolving gel was set, components
for two stacking gels consisted of 1.5 ml of 40% acrylamide,
1.5 ml of 25% glycerol, 1.5 ml of 0.45 M Tris base buffer, and
3 ml of ultrapure water. After the addition of 25 ml of 20% am-
monium persulfate and 5 ml of TEMED, the components
were mixed and poured on top of the resolving gel and an
8-well comb was inserted to create loading wells. Gels were
rinsed with water and loaded in an electrophoresis tank con-
taining electrophoresis buffer (18.15 g Tris base, 8.37 g boric
acid, and 558 mg ethylenediaminetetraacetic acid (EDTA) in
1.5 L of ultrapure water; pH 7) maintained at 4C. Labeled
samples (5 ml) and internal standard (2 ml) were loaded on
each of the six center lanes. Internal standard and disaccha-
ride standards (DdiHA, Ddi0S, Ddi6S, and Ddi4S), made by
chondroitinase digestion of HA polymer (ICN Immunobiologi-
cals, Lisle, IL) and CS (J-Flex, Springtime, Inc., Cockeysville,
MD), were loaded in the two outside lanes for band conﬁrma-
tion. Electrophoresis was performed with a constant 500 V
power source (Biorad, Hercules, CA) for 2 h. After electropho-
resis, gelswere removed from their glassplates, illuminatedby
ultraviolet (UV) light (GE Healthcare), and digitally imaged us-
ing the Kodak 1D system (Eastman Kodak, New Haven, CT).
Images were analyzed with image analysis software (Kodak
1D) and quantities of GAG in each sample were calculated.
Average molecular weights (kDa) of CS chains in individ-
ual fractions from the Superose 6 column were estimated by
the relationship between the experimentally determined
number of repeating disaccharides and the partition coefﬁ-
cient (KD) for the column used, as previously described
29.
Partition coefﬁcient (KD) was estimated from
KD ¼ Ve V0
Vt V0
where Ve is the elution volume of the fraction, V0 is the void
volume of the column and Vt is the total volume of the col-
umn31. The molecular mass of the typical CS disaccharide
unit was assumed to be 44629.
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The KruskalleWallis test was performed to determine dif-
ferences between groups for each gel ﬁltration fraction, as
well as for area under the curve (AUC) for total GAG con-
centration. P< 0.05 was considered signiﬁcant. Sensitivity,
speciﬁcity, positive predictive value, and negative predictive
value of the SF CS chain length to discriminate between OC
injured and normal (rested and exercised values combined)
joints were determined by Fisher’s exact test. Calculations
were made for each CS disaccharide and for all three CS
disaccharides combined.
Results
Fluorotagged CS and HA digestion products from SF,
serum, and cartilage were separated by FACE according
to chain length (fraction number) and quantitated in mg/ml
of body ﬂuid or mg/mg of cartilage (wet weight). Recovery
of HA polymer standard (200 mg) from both the Sephacryl
S-1000 and Superose 6 columns, as analyzed by FACE,
was >95%.CHONDROITIN SULFATE
Data from FACE analysis of SF from all horses (rested, ex-
ercised, andOC injury groups) are shown asmeanCS disac-
charide content for each fraction from Superose 6
chromatography [Fig. 1(A)e(C)]. SF from OC injury joints
contained CS that had larger peak chain lengths than that
from the rested and exercised groups. The peak fraction of
CS from rested horseswasatB20,whichhadanaveragemo-
lecular mass of 11.6 kDa. In the exercised group, the peak
fraction of CS was at B19 for Ddi0S and Ddi6S, but B20 for
Ddi4S, with an average molecular mass of 15.6 kDa. In con-
trast, the peak fraction of CS from the OC injury group was at
B18, with an average molecular mass of 18.7 kDa. Total CS
concentration (AUC standard deviation (SD)) in SF from
OC injury joints was 25.01 14.49 mg/ml, and there were no
signiﬁcant differences when compared to 33.77 18.87 mg/
ml for the rested group and 33.19 18.62 mg/ml for the exer-
cised group [Fig. 1(A)e(C)].
Sensitivity and speciﬁcity of the SF CS assay ranged
from 82% to 100% (Table I). For these calculations, Super-
ose 6 fractionB18 was used as a cut-off point for peak SFFig. 1. Plot of mean SF and cartilage CS concentrations (mg/ml of SF or mg/mg of cartilage; þSD) vs Superose 6 fraction number. Chain length
progressively decreases from fraction B11 to B24. (A)e(C) CS in SF from horses with normal joints after rest and exercise (n¼ 9 each; same
joints compared) and from horses undergoing arthroscopic surgery for OC fragment removal (n¼ 11). Note that CS chain length in SF from
OC injured joints is longer than that seen in the rested and exercised groups. (D) CS in cartilage from the same horses undergoing arthro-
scopic surgery for OC fragment removal (n¼ 9). Note that CS chain length in cartilage from OC joints is similar to that seen in the SF
from these joints. Differences between groups (P< 0.05): þ e OC injury vs rested; * e OC injury vs rested and exercised; # e OC injury
vs exercised.
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used as a cut-off point for normal (rested and exercised)
joints (Fig. 2). Visual examination of the diagnostic perfor-
mance of the SF CS assay further conﬁrms that the
Ddi0S and Ddi6S assays had the highest probability of cor-
rectly identifying normal horses (negative predictive val-
ue¼ 100%). In contrast, Ddi4S had the highest probability
of correctly identifying OC injured horses (positive predic-
tive value¼ 91%).
Cartilage was available only from the OC injury group for
analysis of CS disaccharide content [Fig. 1(D)]. The peak
fraction of CS was at B18, which corresponds with peak
fraction in SF from these same joints [Fig. 1(A)e(C)], with
a molecular mass of 18.7 kDa. Total CS content of the car-
tilage (AUC SD) from OC injury joints was highly variable
(Ddi0S¼ 0.49 0.55 mg/mg; Ddi6S¼ 2.78 3.20 mg/mg;
Ddi4S¼ 2.53 2.76 mg/mg).
Chondroitin-6-sulfate was not detected in the serum. CS
peaked at B18 (18.7 kDa) in serum from horses with OC in-
jury. Serum Ddi0S and Ddi4S content in fraction B18 from
these horses was signiﬁcantly different from rested horses
[P< 0.05; Fig. 3(A) and (B)].
HYALURONAN
Total SF HA content (AUCSD) was signiﬁcantly de-
creased for the OC injury group (831 503 mg/ml) com-
pared with the rested group (1838 529 mg/ml; P< 0.05;
Fig. 4). Total SF HA content for the exercised group was
1385 511 mg/ml, which was not signiﬁcantly different
from the other two groups.
SF from the rested and exercised groups showed promi-
nent HA peaks in fractions A13 and B11 (Fig. 4). Similarly,
SF from the OC injury group showed an HA peak at B11,
but the Sephacryl S-1000 fractions showed a non-distinct
peak at A15, indicating a signiﬁcant, discriminative loss of
the largerHA chains seen in fractionA13 in the rested and ex-
ercised groups. Additionally, HA fractions to the right of both
peaks for the rested group (A13 and B11) were signiﬁcantly
higher than both the exercised and injured groups, implying
effects of both exercise and injury on the SF HA proﬁles.
Cartilage from the OC injury joints showed an HA peak
centered at B10 (Fig. 5). Mean total HA content (AUC SD)
in these samples was 0.18 0.16 mg/mg of cartilage. Total
serum HA concentrations ranged from 0.38 0.23 mg/ml for
samples taken 1 h after stress testing (exercised group) to
0.82 1.07 mg/ml for samples from the rested horses. Se-
rum HA concentrations were quite variable within groups
and there were no signiﬁcant differences in total serum
HA between groups. Only in fraction B14 did serum HA
show signiﬁcantly lower values for the OC injury group com-
pared with the exercised group (in samples drawn immedi-
ately after and 1 h later; P< 0.05).
Table I
Sensitivity, specificity, positive predictive value, and negative pre-
dictive value of SF CS assay to discriminate between OC injured
and normal (rested and exercised values combined) joints
Disaccharide Sensitivity
(%)
Speciﬁcity
(%)
Positive
predictive
value (%)
Negative
predictive
value (%)
Ddi0S 100 82 64 100
Ddi6S 100 86 70 100
Ddi4S 91 94 91 94
Ddi0S/Ddi6S/Ddi4S 96 87 76 98Discussion
We report a biochemical analysis of SF and serum CS
and HA which discriminates between normal rested and ex-
ercised joints and post-injury joints. SF CS and HA both
showed signiﬁcant changes as a result of exercise and
OC injury.
Fig. 2. Horizontal scatter plot of peak SF CS Superose 6 fractions
for each joint in the OC injury, rested, and exercised groups. The
vertical dashed lines represent the dividing line between fractions
B18 (18.7 kDa) and B19 (15.6 kDa). The short vertical solid lines
represent the mean value for each group.
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in the SF of OC injury joints. Superose 6 gel chromatogra-
phy combined with FACE analyses revealed a statistically
signiﬁcant injury-associated increase in CS chain size
(18.7 kDa) when compared to rested horses (11.6 kDa),
with exercise producing an intermediate chain length
(15.6 kDa). The origin of elongated CS chains in SF from in-
jured joints is unknown. Other investigators have suggested
that much of the SF CS derives from the articular carti-
lage32. Although CS chain length in cartilage from the OC
Fig. 3. Plot of mean serum CS concentrations (mg/ml þ SD) vs
Superose 6 fraction number. (A) Ddi0S in serum from horses with
normal joints after rest and exercise (collected immediately after
and then 1 h after stress test; n¼ 9) and from horses undergoing
arthroscopic surgery for OC fragment removal (n¼ 9). (B) Ddi4S
in serum from same horses. Note the peaks in OC injury serum
occur in fraction B18 (18.7 kDa), similar to those seen in SF and
cartilage of this group (see Fig. 1). Differences between groups
(P< 0.05): þ e OC injury vs rested; # e OC injury vs exercised.injury joints was similar to that seen in the SF of these joints
(Fig. 1), cartilage specimens were not available from the
normal horses in this study to make the same comparison.
As a result, we were unable to conﬁrm that CS composition
in SF is a reﬂection of that seen in the cartilage of the same
joint. Similar comparisons between cartilage and SF CS
chain length in normal rested and exercised groups would
be needed to determine whether or not SF CS chain length
data provided by this assay may provide a direct indicator of
the CS composition of the cartilage.
The apparent ability of the assay to distinguish the effects of
OC injury on SF CS chain length could lead to diagnostic ap-
plications. Negative predictive value is an important parame-
ter of clinical relevance because it helps the clinician know
the probability that a joint that is classiﬁed as negative by
the assay is indeed normal (non-injured). In contrast, positive
predictive value helps the clinician to know the probability that
a joint that is classiﬁed as positive by the assay is indeed in-
jured. The assay performed well in both regards, with Ddi0S
and Ddi6S more likely to correctly identify normal joints
(100%) and Ddi4S more likely to identify injured joints (91%).
Dimethylmethylene blue (DMMB) assays could be done
on Superose 6 fractions instead of FACE analysis for deter-
mination of sulfated GAG chain size. This would make the
assay much faster and simpler, as well as less expensive
Fig. 4. Plot of meanSFHA concentrations (mg/mlþ SD) vs Sephacryl
S-1000 fraction (A7eA24) or Superose 6 fraction(B7eB23) from
horses with normal joints after rest and exercise (n¼ 9 each; same
joints compared) and from horses undergoing arthroscopic surgery
for OC fragment removal (n¼ 11). Differences between groups
(P< 0.05): þ e OC injury vs rested; * e OC injury vs rested and ex-
ercised; #eOC injury vs exercised;7e rested vs OC injury and ex-
ercised;N rested vs exercised. Total HA concentration (mg/ml; AUC)
for the OC injury group was signiﬁcantly lower than for the rested
group (P< 0.05).
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these fractions is essentially CS because of Superose 6 pu-
riﬁcation (data not shown).
Abnormally long CS chains have been reported for newly
synthesized aggrecan in post-injury canine OA cartilage28.
Repeating disaccharides of the CS chain are added by the
alternating addition of the monosaccharides, N-acetylgalac-
tosamine (GalNAc) and glucuronic acid (GlcA), to the non-
reducing terminal of the elongating chain. Two enzymes,
N-acetylgalactosaminyltransferase and glucuronosyltrans-
ferase, are required to facilitate this process34. Based on
in vitro studies using odd- and even-numbered oligosaccha-
rides with a non-reducing terminal, it was reported that
non-sulfated GalNAc or 6-sulfated N-acetylgalactosamine
(GalNAc6S) were excellent receptors for enzymatic addition
of GlcA and thus facilitated elongation of the CS chain. How-
ever, in the same model, 4-sulfated GalNAc blocked further
elongation of the CS chain. Furthermore, presence of 4-
sulfated GalNAc in the penultimate position of the non-
reducing terminal also prevented CS chain elongation35. In
contrast, another study showed oligosaccharides that are
4-sulfated on the penultimate GalNAc at the non-reducing
end act as receptors36. These latter ﬁndings are comparable
with our previous work, in which the presence of GalNAc4S
andGlcAeGalNAc4S at the non-reducing terminal wasmore
common in articular cartilage from horses with OC fragments
than from normal joints1. It has been suggested that impaired
secretion of proteoglycan from the Golgi cisternae may occur
inOA cartilage, thus resulting in abnormally longCS chains28.
Mean total CS in SF in our study (25.01 mg/ml, injured;
33.77 mg/ml, rested; 33.19 mg/ml, exercised) compared
closely with those values reported for rabbits (38 4 mg/
ml)32. Mean total CS in the cartilage from the OC injury group
(5.81 6.44 mg/mg) was highly variable and similar to that re-
ported for mouse cartilage (2.6e4.6 mg/mg)37, but much lower
than that reported for rabbit articular cartilage (27.8 mg/mg)32.
Our ﬁnding that Ddi6S was not detectable in serum is
similar to previous reports in which only low or trace
amounts were found in serum of rabbits and human pa-
tients6,38. In the latter study, total serum Ddi0S and Ddi4S
data were interpreted by the investigators as being signiﬁ-
cantly different between human OA patients and controls.
Fig. 5. Plot of mean cartilage HA concentrations (mg/mgþSD) vs
Superose 6 fraction (B7eB23) from horses with OC injury (n¼ 9).
Mean total HA content in these samples was 0.18 0.16 mg/mg
(AUCSD) of cartilage, with the peak occurring at B10.In our study, both serum Ddi0S and Ddi4S showed signiﬁ-
cant differences between the OC injured and rested groups.
This difference was not in total Ddi0S or Ddi4S, but in a sin-
gle peak at the B18 (18.7 kDa) fraction in the OC injured
horses [Fig. 3(A) and (B)]. This peak may be a reﬂection
of the Ddi0S and Ddi4S peaks seen in this fraction in both
the articular cartilage and SF. Thus, it appears that the high-
est concentrations of Ddi0S and Ddi4S in serum, SF, and
cartilage of the OC injured horses is in fraction B18, which
has an average molecular weight of 18.7 kDa. In contrast,
however, this apparent relationship was not seen in the se-
rum and SF Ddi0S and Ddi4S peaks in the rested and exer-
cised horses. It is therefore difﬁcult to draw any conclusions
regarding the usefulness of serum CS data as an indicator
of events in the joint. It has been shown that approximately
one-half of the Ddi4S contained in serum is released from
platelets and therefore plasma may be better than serum
for monitoring CS38.
Our ﬁndings in OC injured joints agree with previous re-
ports that SF HA is decreased in chain length21,22 and con-
centration3,18,20,39 in OA. Additionally, exercise had
signiﬁcant effects on the SF HA proﬁle (Fig. 4). Regulation
of HA synthesis and chain length is not well understood. HA
is synthesized by HA synthase, which has three isoforms:
HAS1,HAS2, andHAS340. These isoformshavedifferent en-
zymatic properties, such as rate of synthesis and chain
length, and may be stimulated or inhibited by growth factors
and cytokines41. It has been reported that HAS3 makes
shorter chains than HAS1 and HAS240. Induction of HAS3
by interleukin-1b has been shown to be signiﬁcantly high in
OA synovial cells, whichmay relate to the synovial inﬂamma-
tion in this disease42,43. Thus, shorter HA chain length in in-
jured joints may be a result of synthesis of shorter chains by
HAS3, as well as degradation of longer chains by oxygen-
derived free radicals released by inﬂammatory cells44e46.
Synovial cell HAS message expression is higher in vivo
than in cell culture, especially in arthritic synovium and
has been associated with the effusion that accompanies
such joints41. Transforming growth factor (TGF-b1) is a ma-
jor stimulator of HA synthesis in human synovium and might
be involved in the mechanisms of joint swelling in inﬂamma-
tory and degenerative joint diseases44. Increased intra-
articular pressure results in increased HA synthesis32,47.
We did not determine HA synthesis rates in these horses.
Thus, injury-induced decrease in total SF HA concentration
may be dilutional due to synovial effusion, in spite of possi-
ble increased synthesis. SFs from normal human knees
have yielded HA concentrations from 1.45 to 2.94 mg/
ml21,48. Values of 3.6 mg/ml have been reported for rabbit
SF32. Our SF HA concentration values (normal, rested e
1.84 0.53 mg/ml; OC injury e 0.83 0.50 mg/ml) were
similar to those previously reported for the horse (normal e
1.26 0.26 mg/ml; arthritic e 0.58 0.16 mg/ml)39. By
using different assay methods, other investigators have
obtained lower values, but have shown similar differences
between normal and arthritic joints in horses3.
Mean total cartilage HA from the OC injury joints
(0.18 0.16 mg/mg) was lower than that reported for rabbit
cartilage (0.42 mg/mg)32 and for human cartilage
(0.5e2.5 mg/mg)49. The HA chains in our cartilage samples
were relatively uniform in size, with the majority being in
fractions B9eB11 (Fig. 5). This is in contrast to a previous
report on HA chain size in human articular cartilage, in
which values ranged from 2 106 in immature cartilage to
3 105 in mature cartilage49. We did not fractionate our car-
tilage digests on the Sephacryl S-1000 column as was done
in that study and therefore, we may have missed the larger
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our lower total HA content in cartilage.
Exercise has been shown to increase serum HA concen-
trations in both normal subjects and in patients with rheuma-
toid arthritis50,51. A study involving African American and
Caucasian patients supported the use of serum HA concen-
trations as a biomarker of radiographic OA52. In contrast, an-
other study showed no correlation between serum HA
concentrations andWestern Ontario andMacMaster Univer-
sities Osteoarthritis Index (WOMAC) or Kellgren/Lawrence
radiological grade, in spite of signiﬁcant differences in serum
HA between normal healthy controls and patients with knee
OA53. Serum HA concentrations in our study were quite vari-
able and did not discriminate between rested, exercised, and
OC injury groups. It is probable that the horses with OC injury
in our study were in a much earlier stage of OA than patients
seen in human studies. If so, this could account for the differ-
ence in results rather than a species difference. The lower
limit of detection for our assay appears to be similar to as-
says used in previous reports and unlikely accounts for the
differences. We did not consider the statistically signiﬁcant
difference in serum HA between the OC injured and exer-
cised joints in fraction B14 to be of clinical signiﬁcance.
Our study had limitations. Although our assay had very
high negative and positive predictive values for joint injury,
the assay is difﬁcult and time-consuming. As mentioned,
adaptation to a DMMB protocol may increase the practical-
ity of measuring SF CS chain length. Another limitation was
lack of availability of cartilage samples from the normal
rested and exercised horses in the study. As a result, we
were unable to conﬁrm the apparent relationship between
SF CS and corresponding values in the cartilage.
In conclusion, we have used a combination of gel chroma-
tography and FACE to demonstrate that there was a signiﬁ-
cant incremental increase in SF CS chain size as a result of
exercise and OC injury, compared with the effects of rest.
We also demonstrated that OC injury caused a signiﬁcant de-
crease in both SF HA chain length and total concentration,
when compared to rest. Similarly, exercise resulted in signiﬁ-
cant decreases in SFHA chain length, with a concurrent, non-
signiﬁcant decrease in total concentration, compared to rest.
Based on these ﬁndings, chain length analysis of SF CS
and HAmay provide a useful tool for evaluation of joint health.
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